This Article Full Text Full Text (PDF) Services Download to citation manager Citing Articles Citing Articles via HighWire PubMed PubMed Citation

Cerebrospinal Fluid Amyloid ß₄₂/Phosphorylated Tau Ratio Discriminates Between Alzheimer's Disease and Vascular Dementia

¹ Departments of Neurology and ² Geriatric Medicine, ³ Laboratory of Pediatrics and Neurology, Radboud University Nijmegen Medical Centre, The Netherlands.

Address correspondence to Marcel M. Verbeek, PhD, MSc, Radboud University Nijmegen Medical Centre, Laboratory of Pediatrics and Neurology (830 LKN), P.O. Box 9101, 6500 HB Nijmegen, The Netherlands. E-mail: m.verbeek{at}cukz.umcn.nl

Abstract

Background. The differentiation of Alzheimer's disease (AD) from vascular dementia (VaD) is hampered by clinical diagnostic criteria with disappointing sensitivity and specificity. The objective of this study was to investigate whether cerebrospinal fluid (CSF) levels of total tau protein (t-tau), amyloid ß₄₂ protein (Aß₄₂), and tau phosphorylated at threonine 181 (p-tau₁₈₁) are useful biomarkers to distinguish AD patients from VaD patients.

Methods. We measured CSF levels of p-tau₁₈₁, Aß₄₂, and t-tau in 86 patients with a clinical diagnosis of AD or VaD and in 30 control participants.

Results. Optimal differentiation between AD and VaD was achieved by using the ratio of the CSF levels of Aß₄₂ and p-tau₁₈₁ (Q Aß₄₂/p-tau) with sensitivity, specificity, positive and negative predictive values all 85%.

Conclusions. Our results support further efforts to prospectively validate the use of Q Aß₄₂/p-tau as a biomarker to discriminate between AD and VaD.

This article has been cited by other articles:

				I. Petrushina, A. Ghochikyan, M. Mktrichyan, G. Mamikonyan, N. Movsesyan, H. Davtyan, A. Patel, E. Head, D. H. Cribbs, and M. G. Agadjanyan Alzheimer's Disease Peptide Epitope Vaccine Reduces Insoluble But Not Soluble/Oligomeric A{beta} Species in Amyloid Precursor Protein Transgenic Mice J. Neurosci., November 14, 2007; 27(46): 12721 - 12731. [Abstract] [Full Text] [PDF]

				D de Jong, R W M M Jansen, Y A L Pijnenburg, W J A van Geel, G F Borm, H P H Kremer, and M M Verbeek CSF neurofilament proteins in the differential diagnosis of dementia J. Neurol. Neurosurg. Psychiatry, September 1, 2007; 78(9): 936 - 938. [Abstract] [Full Text] [PDF]

				N. L. Bastard, M. V. Buggenhout, E. D. Leenheir, J.-J. Martin, P. P. D. Deyn, and S. Engelborghs Letter to the Editor: LOW SPECIFICITY LIMITS THE USE OF THE CEREBROSPINAL FLUID AB1-42/P-TAU181P RATIO TO DISCRIMINATE ALZHEIMER'S DISEASE FROM VASCULAR DEMENTIA J. Gerontol. A Biol. Sci. Med. Sci., August 1, 2007; 62(8): 923 - 924. [Full Text] [PDF]

				D. de Jong, R. W. M. M. Jansen, B. P. H. Kremer, and M. M. Verbeek POTENTIAL PITFALLS IN THE ANALYSIS OF CSF BIOMARKERS IN ALZHEIMER'S DISEASE AND VASCULAR DEMENTIA J. Gerontol. A Biol. Sci. Med. Sci., August 1, 2007; 62(8): 924 - 925. [Full Text] [PDF]

				T. S.M. Reijn, M. O. Rikkert, W. J.A. van Geel, D. de Jong, and M. M. Verbeek Diagnostic Accuracy of ELISA and xMAP Technology for Analysis of Amyloid {beta}42 and Tau Proteins Clin. Chem., May 1, 2007; 53(5): 859 - 865. [Abstract] [Full Text] [PDF]